Bupivacaine HCl collagen-matrix implant — Competitive Intelligence Brief

Bupivacaine HCl collagen-matrix implant (Bupivacaine HCl collagen-matrix implant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management / Surgery.

phase 3 Local anesthetic Voltage-gated sodium channels Pain management / Surgery Small molecule

Target snapshot

Bupivacaine HCl collagen-matrix implant (Bupivacaine HCl collagen-matrix implant) — Innocoll. Bupivacaine HCl is released from a collagen matrix implant to provide local anesthesia at the surgical site.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine HCl collagen-matrix implant TARGET	Bupivacaine HCl collagen-matrix implant	Innocoll	phase 3	Local anesthetic	Voltage-gated sodium channels
PIB 0.2% ropivacaine	PIB 0.2% ropivacaine	University Health Network, Toronto	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Dyclonine hydrochloride mucilage	Dyclonine hydrochloride mucilage	Peking Union Medical College Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Prilocaine 2.5%	Prilocaine 2.5%	Express Specialty Pharmacy	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
etomidate, fentanyl, and lidocaine	etomidate, fentanyl, and lidocaine	Drexel University College of Medicine	marketed	Anesthetic combination (hypnotic + opioid + local anesthetic)	GABA-A receptor (etomidate), mu opioid receptor (fentanyl), voltage-gated sodium channels (lidocaine)
Bupivacaine FNB	Bupivacaine FNB	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic	Voltage-gated sodium channels
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class